Download PDF
Thromb Haemost 1995; 74(05): 1231-1234
DOI: 10.1055/s-0038-1649917
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Increased Plasma Thrombin-Antithrombin III Complex Levels in Non-Insulin Dependent Diabetic Patients with Albuminuria Are Reduced by Ethyl Icosapentatenoate

Hiroyuki Shimizu
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Ken-Ichi Ohtani
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Yoshito Tanaka
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Akira Fukatsu
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Yutaka Uehara
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Noriyuki Sato
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
,
Masatomo Mori
The First Department of Internal Medicine, Gunma University School of Medicine, Maebashl Gunma, Japan
› Author Affiliations
Further Information

Publication History

Received 16 January 1995

Accepted after resubmission 20 July 1995

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Hypercoagulability may increase the risk of cardiovascular disease (CVD) in diabetic patients with albuminuria. Plasma thrombin-antithrombin III complex (TAT) levels, representing a functional state of clotting system, were studied in one hundred and fifteen non-insulin- dependent diabetic (NIDDM) patients. The patients were divided into three groups according to the urine albumin index (UAI: mg/g Cr): Group A; UAI<30, Group B; 30<UAI<300, Group C; UAI>300. The effect of albuminuria on plasma TAT levels was significant (p<0.02). Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks significantly (p<0.0005) decreased plasma TAT levels. These data indicate that the degree of diabetic albuminuria is related to plasma TAT levels in NIDDM patients and that treatment with EPA may reduce TAT levels and possibly therefore the rate of development of CVD in patients with NIDDM.

 

  • References

  • 1 Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-365
    CrossrefPubMedGoogle Scholar
  • 2 Vaeth M, Schmitz A. Microalbuminuria: a major risk factor in non-insulin dependent diabetes. A 10-year follow-up study of 503 patients Diabetic Med 1988; 5: 126-134
    CrossrefPubMedGoogle Scholar
  • 3 Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125
    CrossrefPubMedGoogle Scholar
  • 4 van Wersch JW J, Westerhuis LW J J M, Venekamp WJ R R. Coagulation activation in diabetes mellitus. Hemostasis 1990; 20: 263-269
    PubMedGoogle Scholar
  • 5 Ceriello A, Giugliano D, Quatrano A, Marchi E, Barbanti M, Lefevre PJ. Evidence for a hyperglycemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33: 163-167
    CrossrefPubMedGoogle Scholar
  • 6 Murakami T, Komiyama Y, Egawa H, Murata K. Elevation of Factor XIa-α1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy. Diabetes 1993; 42: 233-238
    CrossrefPubMedGoogle Scholar
  • 7 Takahashi H, Tsuda A, Tatewaki W, Wada K, Niwano H, Shibata A. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma level of thrombin-antithrombin III complex and plasma-alpha2-plasmin inhibitor complex. Thromb Res 1989; 55: 727-735
    CrossrefPubMedGoogle Scholar
  • 8 Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988; 31: 142-145
    CrossrefPubMedGoogle Scholar
  • 9 Bent-Hansen L, Deckert T. Metabolism of albumin and fibrinogen in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res 1988; 7: 159-164
    PubMedGoogle Scholar
  • 10 Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205-1209
    CrossrefPubMedGoogle Scholar
  • 11 Nathan DM, Rosenbaum C, Protasowicki VD. Single-void urine samples can be used to estimate quantitative microalbuminuria. Diabetes Care 1987; 10: 414-418
    CrossrefPubMedGoogle Scholar
  • 12 Nelson KG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH. Assessment of risk of overt nephropathy in diabetic patients for albumin excretion in untimed urine specimens. Ann Intern Med 1991; 151: 1761-1765
    CrossrefPubMedGoogle Scholar
  • 13 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin- antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Winocour PH, Durrington PN, Ishola M, Anderson DC, Cohen H. Influence of proteinuria on vascular disease, blood pressure and lipoproteins in insulin-dependent diabetes mellitus. Br Med J 1987; 294: 1648-1651
    CrossrefPubMedGoogle Scholar
  • 15 Jones SL, Close CF, Matlock MJ, Jarrett RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentrations in insulin-dependent diabetics with microalbuminuria. Br Med J 1989; 298: 487-490
    CrossrefPubMedGoogle Scholar
  • 16 Deckert T, Kofoed-Enevoldsen A, Norgaard K, Borch-Johnsen K, Feldt- Rasmussen B, Jensen T. Microalbuminuria: Implications for micro-and macrovascular disease. Diabetes Care 1992; 15: 1181-1191
    CrossrefPubMedGoogle Scholar
  • 17 Ceriello A, Giugliano D, Quatraro A, Marchi E, Barbanti M, Lefèbvre P. Evidence for a hyperglycemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia 1990; 33: 163-167
    CrossrefPubMedGoogle Scholar
  • 18 Ceriello A, Quatraro A, Marchi E, Barbanti M, Russo PD, Lefebvre P, Giugliano D. The role of hyperglycemia-induced alterations of anti thrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus. Diabetic Med 1990; 7: 343-348
    CrossrefPubMedGoogle Scholar
  • 19 Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990; 227: 347-353
    CrossrefPubMedGoogle Scholar
  • 20 Haglund O, Mehta JL, Saldeen T. Effects of fish oil on some parameters of fibrinolysis and lipoprotein (a) in healthy subjects. Am J Cardiol 1994; 74: 189-192
    CrossrefPubMedGoogle Scholar
  • 21 Shahar E, Folsom AR, Wu KK. Association on fish intake and dietary n-3 polyunsaturated fatty acids with a hypocoagulable profile. Arterioscler Thromb 1993; 13: 1205-1212
    CrossrefPubMedGoogle Scholar
  • 22 Hansen J-B, Olsen JO, Wilsgard L, Østerud B. Effects of dietary supplementation with cod-liver oil on monocyte thromboplastin activity, coagulation and fibrinolysis. 1989; J Intern Med 225 Suppl (Suppl. 01) 133-139
    CrossrefPubMedGoogle Scholar
  • 23 Miller ME, Anagnostou AA, Ley B, Marshall P, Steiner M. Effect of fish oil concentrations on hemorheological and hemostatic aspects of diabetes mellitus: a preliminary study. Thromb Res 1987; 47: 201-214
    CrossrefPubMedGoogle Scholar
  • 24 Boneu B, Abbal M, Plante J, Bieme R. Factor VUI-complex and endothelial cell damage. Lancet 1975; 1: 1430
    PubMedGoogle Scholar
  • 25 Editorial: Factor VUI-related antigen and vasculitis. Lancet 1988; 1: 1203-1204
    PubMed
  • 26 Stoffersen E, Jorgensen KA, Dyerberg J. Antithrombin III and dietary intake of polyunsaturated fatty acids. Scand J Clin Lab Invest 1982; 42: 83-86
    CrossrefPubMedGoogle Scholar
  • 27 Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J. The effect of N-6 and N-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. Thromb Haemost 1983; 50: 543-546
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Shimizu H, Sato N, Tanaka Y, Kashima K, Ohtani K, Mori M. Effect of eicosapentaenoic acid ethyl on albuminuria in NIDDM patients. Diabetes Care 1993; 16: 1406-1408
    CrossrefPubMedGoogle Scholar
  • 29 Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Longterm effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of noninsulin dependent diabetic patients. Diabetes Res Clin Pract 1985; 28: 35-40
    PubMedGoogle Scholar